These findings further underscore the potential of PDPK1 as a therapeutic target, as they indicate that PDPK1 or SGK3 can act as druggable targets in the treatment of hormone‐refractory PCa as single agents or in combination with chemotherapeutics as components of a multitargeted therapy regimen. The gene discussed is SGK3; the disease is posterior cortical atrophy.